Profile Response Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com


Molecular Profile CD274 positive
Therapy Camrelizumab
Indication/Tumor Type esophagus squamous cell carcinoma
Response Type predicted - sensitive

Filtering

  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Molecular Profile Indication/Tumor Type Response Type Therapy Name Approval Status Evidence Type Efficacy Evidence References
CD274 positive esophagus squamous cell carcinoma predicted - sensitive Camrelizumab Phase I Actionable In a Phase I trial, Camrelizumab (SHR-1210) treatment resulted improved objective response rate (46.7%, 7/15 vs 11.1%, 1/9, p>0.05) and disease control rate (66.7%, 10/15 vs 33.3%, 3/9) in patients with CD274 (PD-L1)-positive advanced esophageal squamous cell carcinoma compared to patients with CD274 (PD-L1)-negative tumors (PMID: 29358502; NCT02742935). 29358502
PubMed Id Reference Title Details
(29358502) Safety, Activity, and Biomarkers of SHR-1210, an Anti-PD-1 Antibody, for Patients with Advanced Esophageal Carcinoma. Full reference...